Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

Celik O, Hascalik S, Elter K, Tagluk ME, Gurates B, Aydin NE.

Hum Reprod. 2008 Nov;23(11):2458-65. doi: 10.1093/humrep/den246. Epub 2008 Aug 2.

PMID:
18676981
2.

Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways.

Cvek B.

Hum Reprod. 2009 Nov;24(11):2967; author reply 2967-8. doi: 10.1093/humrep/dep294. Epub 2009 Aug 17. No abstract available.

PMID:
19687055
3.

Chemoprotective effect of a nuclear factor-kappaB inhibitor, pyrrolidine dithiocarbamate, against cisplatin-induced testicular damage in rats.

Ilbey YO, Ozbek E, Simsek A, Cekmen M, Otunctemur A, Somay A.

J Androl. 2009 Sep-Oct;30(5):505-14. doi: 10.2164/jandrol.108.006270. Epub 2009 Feb 19.

4.

Application of the nuclear factor-κB inhibitor pyrrolidine dithiocarbamate for the treatment of endometriosis: an in vitro study.

Zhang JJ, Xu ZM, Dai HY, Ji XQ, Duan YY, Zhang CM, Qin DY.

Fertil Steril. 2010 Dec;94(7):2942-4. doi: 10.1016/j.fertnstert.2010.05.009. Epub 2010 Jun 19.

PMID:
20561612
5.

Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.

Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, Ponzetto C.

Eur J Cancer. 2008 Apr;44(6):876-84. doi: 10.1016/j.ejca.2008.02.022. Epub 2008 Mar 14.

PMID:
18342500
6.

Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window.

Nurmi A, Vartiainen N, Pihlaja R, Goldsteins G, Yrjänheikki J, Koistinaho J.

J Neurochem. 2004 Nov;91(3):755-65.

7.

Pyrrolidine dithiocarbamate attenuate shock wave induced MDCK cells injury via inhibiting nuclear factor-kappa B activation.

Li X, He D, Zhang L, Xue Y, Cheng X, Luo Y.

Urol Res. 2007 Aug;35(4):193-9. Epub 2007 Jun 12.

PMID:
17562036
8.

Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation.

Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, Weissert R.

Eur J Immunol. 2008 Sep;38(9):2401-11. doi: 10.1002/eji.200838413.

9.

Agents blocking the nuclear factor-kappaB pathway are effective inhibitors of endometriosis in an in vivo experimental model.

González-Ramos R, Van Langendonckt A, Defrère S, Lousse JC, Mettlen M, Guillet A, Donnez J.

Gynecol Obstet Invest. 2008;65(3):174-86. Epub 2007 Nov 20.

PMID:
18025832
10.

Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.

Exp Cell Res. 2009 Aug 15;315(14):2471-8. doi: 10.1016/j.yexcr.2009.04.019. Epub 2009 May 3.

PMID:
19410573
11.

Simultaneous proteosome inhibition and heat shock protein induction by bortezomib is beneficial in experimental pancreatitis.

Szabolcs A, Biczó G, Rakonczay Z, Tiszlavicz L, Halm G, Wittmann T, Takács T.

Eur J Pharmacol. 2009 Aug 15;616(1-3):270-4. doi: 10.1016/j.ejphar.2009.05.019. Epub 2009 May 30.

PMID:
19486901
12.

Inhibition of nuclear factor-kappa B activation reduces glycerol-induced renal injury.

de Jesus Soares T, Costa RS, Balbi AP, Coimbra TM.

J Nephrol. 2006 Jul-Aug;19(4):439-48.

PMID:
17048201
13.

Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma.

Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA, Conley BA.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1400-12. Epub 2005 Jul 11.

PMID:
16005577
14.

Effects of dimethyl sulfoxide, pyrrolidine dithiocarbamate, and methylprednisolone on nuclear factor-kappaB and heat shock protein 70 in a rat model of hemorrhagic shock.

Bini R, Olivero G, Trombetta A, Castagna E, Cotogni P.

J Trauma. 2008 Apr;64(4):1048-54. doi: 10.1097/TA.0b013e318059362e.

PMID:
18404074
15.

Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.

O'Connor O, Wright J, Moskowitz CH, Muzzy J, MacGregor-Cortelli B, Hamlin P, Straus D, Trehu E, Schenkein DP, Zelenetz AD.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S21-2.

PMID:
19791425
16.

Effects of gut barrier dysfunction and NF-kappaB activation on aggravating mechanism of severe acute pancreatitis.

Wang YL, Zheng YJ, Zhang ZP, Su JY, Lei RQ, Tang YQ, Zhang SD.

J Dig Dis. 2009 Feb;10(1):30-40. doi: 10.1111/j.1751-2980.2008.00360.x.

PMID:
19236545
17.

[Inhibition of rat corneal neovascularization by inhibitor of nuclear factor-kappaB].

Wang Y, Zhang MC, Hu YZ, Yu CT.

Zhonghua Yan Ke Za Zhi. 2005 Dec;41(12):1124-8. Chinese.

PMID:
16409768
18.

Proteasome inhibition promotes functional recovery after peripheral nerve reperfusion injury.

Park JW, Kim KM, Oh KJ, Rhyu IJ, Jang HS.

J Trauma. 2009 Mar;66(3):743-8. doi: 10.1097/TA.0b013e3181941218.

PMID:
19276748
19.

Molecular profiles of proteasome inhibition in plasma cell dyscrasias.

Mitsiades CS.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S23-7.

PMID:
19795532
20.

The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model.

He XP, Li XX, Bi YW, Yue WM, Sun WY, Pang XY, Gu XH.

Transplant Proc. 2008 Jun;40(5):1722-6. doi: 10.1016/j.transproceed.2008.01.063.

PMID:
18589180

Supplemental Content

Support Center